Molecular epidemiology and clinical risk factors for rifaximin-non-susceptible Clostridioides difficile infection in South Korea: a prospective, multicentre, observational study by 김도균 et al.
Journal of Global Antimicrobial Resistance 27 (2021) 46–50 
Contents lists available at ScienceDirect 
Journal of Global Antimicrobial Resistance 
journal homepage: www.elsevier.com/locate/jgar 
Molecular epidemiology and clinical risk factors for 
rifaximin-non-susceptible Clostridioides difficile infection in South 
Korea: a prospective, multicentre, observational study 
Dokyun Kim a , Young Ah Kim b , Jung Lim Kim a , Yoon Soo Park c , d , Seok Hoon Jeong a , 
Heejung Kim a , ∗
a Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, South Korea 
b Department of Laboratory Medicine, National Health Insurance Service, Ilsan Hospital, Goyang, South Korea 
c Department of Internal Medicine, National Health Insurance Service, Ilsan Hospital, Goyang, South Korea 
d Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea 
a r t i c l e i n f o 
Article history: 
Received 22 October 2020 
Revised 3 June 2021 
Accepted 20 July 2021 
Available online 25 July 2021 







a b s t r a c t 
Objectives: This study was designed to investigate the molecular epidemiology of Clostridioides difficile 
isolates in South Korea and to evaluate risk factors for rifaximin-non-susceptible C. difficile infection (CDI). 
Methods: A total of 413 patients with CDI from two sentinel hospitals in South Korea were enrolled in 
this study. Putative clinical risk factors for CDI were identified using digital medical records of the pa- 
tients. Pathogen profiles, including antimicrobial susceptibility, toxin production and ribotype, were eval- 
uated for each of the causative C. difficile isolates. 
Results: Of the 413 C. difficile isolates, 81 (19.6%) were shown to be rifaximin-non-susceptible, with the 
most common ribotypes being 018 (56.8%; 46/81), 017 (16.0%; 13/81) and 027 (6.2%; 5/81). Rifaximin- 
non-susceptible C. difficile isolates exhibited higher non-susceptibility rates to most of the other drugs 
tested in this study compared with rifaximin-susceptible isolates. Previous history of pulmonary tubercu- 
losis and prior rifaximin treatment were shown to be associated with the occurrence of rifaximin-non- 
susceptible CDI compared with susceptible CDI. 
Conclusion: Non-susceptibility rates to rifaximin for the C. difficile isolates identified in this study were 
reasonably high with most of the resistant strains belonging to either ribotype 018 or 017. Widespread 
dissemination of these clones may be the result of antimicrobial selection pressure introduced by the 
widespread use of rifaximin. These results suggest that a sustainable surveillance programme for CDI and 
C. difficile resistance is needed in order to better control CDIs and to improve therapeutic efficacy. 
© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial 
Chemotherapy. 
This is an open access article under the CC BY-NC-ND license 






















Clostridioides difficile is a spore-forming, Gram-positive anaer- 
be that is the most common causative pathogen of healthcare- 
ssociated diarrhoea. The incidence of C. difficile infection (CDI) 
as continuously increased over the last few decades, with both 
ealthcare-associated and community-onset diarrhoea increasing 
xponentially throughout the world [ 1 , 2 ]. CDI is a toxin-mediated ∗ Corresponding author. Mailing address: Department of Laboratory Medicine, 
ongin Severance Hospital, Yonsei University College of Medicine, 363 Dongbaekjuk- 
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Y-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) ntestinal disease with a broad spectrum of clinical presentations, 
anging from simple diarrhoea to pseudomembranous colitis, toxic 
egacolon and, in extreme cases, death [3] . CDI usually develops 
n patients after prolonged antimicrobial treatment that may dis- 
urb the balance of the normal intestinal microbiota. Antimicrobial 
esistance enables C. difficile to grow in the presence of antimicro- 
ial drugs, and loss of the commensal microbiota barrier effect and 
he freeing of niches allow C. difficile to colonise and infect the in- 
estine. 
The antimicrobials of choice for the treatment of CDI are 
etronidazole and vancomycin as both of these compounds ex- 
ibit high clearance rates [3] . Resistance to these drugs is still 
are and, to date, decreased susceptibility to metronidazole has 
ot been linked to treatment failure [4] . However, high recurrence ty for Antimicrobial Chemotherapy. This is an open access article under the CC 















































































































ates, ranging from 15–40%, have been reported for CDI. The reason 
ight be that all of the breakpoints are based on serum drug con- 
entrations but effective antimicrobial therapy of CDI requires in- 
racolonic bactericidal concentrations [5] , and the severity of diar- 
hoea may also affect intracolonic concentrations of metronidazole 
ecause it is mostly absorbed in the intestinal tract [6] . In addition, 
hese recurrent illnesses could promote the development of resis- 
ance and result in the generation of more complex infections [7] . 
idaxomicin has been introduced as an active therapeutic alterna- 
ive and has been shown to exhibit efficacy similar to those of the 
ore established antimicrobial drugs, with sustained resolution of 
hese infections [8] . 
Recently, rifaximin, a non-absorbable rifamycin antimicrobial, 
as been proposed as an adjunctive treatment to lower the re- 
urrence of CDI [9] . However, the susceptibility of C. difficile to 
ifaximin has not been widely evaluated, with only a few stud- 
es describing the global non-susceptibility rates for this antibi- 
tic in important C. difficile ribotypes (RTs) 018 and 027 [ 10 , 11 ]. In
oland, RT046 isolates exhibiting rifamycin non-susceptibility were 
ecovered from patients who had been treated with antitubercu- 
osis drugs including rifampicin [12] . Here we conducted a multi- 
entre, observational study designed to investigate the molecular 
pidemiology of rifaximin-non-susceptibility in C. difficile isolates 
rom South Korea and to identify risk factors affecting the dissem- 
nation of rifaximin-non-susceptible clones. 
. Methods 
.1. Study design 
This study was performed using samples from all CDI pa- 
ients identified at two of the general hospitals participating in 
he Global Antimicrobial Resistance Surveillance System (GLASS) 
n South Korea (Kor-GLASS) over a 1-year period (January 2018 to 
ecember 2018) [13] . Clinical information, including demographic 
haracteristics, underlying co-morbidities, previous antimicrobial 
sage, clinical symptoms, laboratory findings and CDI treatment, 
as investigated using the electronic medical records of each hos- 
ital. All clinical C. difficile isolates collected at each of the sentinel 
ospitals were transferred to the analysis centre and were stored 
t –70 °C until evaluation. The requirement for informed consent 
rom the participants was waived by the local ethical committees. 
.2. Definitions 
Hospital-acquired infection was defined as culture-confirmed 
DI occurring after ≥2 calendar days of hospitalisation. Antimicro- 
ial exposure refers to a patient receiving a specific antimicrobial 
reatment within 3 months of sample collection. Severe CDI was 
efined as elevated serum albumin levels ( > 3.0 g/dL) accompanied 
y leukocytosis ( > 15 0 0 0/mm 3 ) or abdominal tenderness [14] . 
.3. Microbiological analysis 
Frozen isolates were thawed and were subcultured anaerobi- 
ally on Brucella blood agar (Becton Dickinson, Cockeysville, MD, 
SA) for 48 h at 35 °C. Bacterial identification was confirmed 
y matrix-assisted laser desorption/ionisation time-of-flight mass 
pectrometry (MALDI-TOF/MS) using a Bruker Biotyper (Bruker 
altonics, Leipzig, Germany). Minimum inhibitory concentrations 
MICs) for ampicillin, cefotetan, clindamycin, imipenem, chloram- 
henicol, tetracycline, moxifloxacin, rifaximin, metronidazole and 
ancomycin were determined by the agar dilution method on Bru- 
ella agar supplemented with 5 μg/mL hemin, 1 μg/mL vitamin 
1 and 5% laked sheep blood according to Clinical and Labora- 
ory Standards Institute (CLSI) guidelines [15] . Bacteroides fragilis 47 TCC 25285, Bacteroides thetaiotaomicron ATCC 29741 and C. diffi- 
ile ATCC 70 0 057 were used as quality control strains. CLSI inter- 
retive criteria were used to determine non-susceptibility to most 
ntimicrobial agents tested [16] . Because CLSI interpretive criteria 
or anaerobes are based on serum drug concentrations, the epi- 
emiological cut-off values proposed by the European Committee 
n Antimicrobial Susceptibility Testing (EUCAST) were used for the 
ntimicrobials for the treatment of CDI such as vancomycin and 
etronidazole [17] . Finally, interpretive criteria for rifaximin were 
etermined using the value of ≤0.015 μg/mL as susceptible. 
Clostridioides difficile toxin genes including tcdA, tcdB, cdtA and 
dtB were detected using PCR as previously described and the fol- 
owing primer pairs: tcdA -F and tcdA -R for tcdA ; NK104 and NK105 
or tcdB; cdtA -pos and cdtA -rev for cdtA ; and cdtB -pos and cdtB -
ev for cdtB [18] . Nucleotide sequences of the RNA polymerase 
subunit gene rpoB were determined using PCR and sequenc- 
ng using a previously described primer [11] and were compared 
ith the sequences from the C. difficile reference strain CD630. 
or all C. difficile isolates, PCR ribotyping was performed using the 
D1-CD1445 primers [19] . Comparison of PCR ribotyping patterns 
as performed visually with known standards (VPI 10463, RT078, 
TCC9689, ATCC43598 and ATCC70057), and the RT patterns with 
t least one band difference were assigned to different RTs. 
.4. Statistical analysis 
Statistical analyses were performed using R software v.3.4.3 (R 
evelopment Core Team 2017; http://www.R-project.org/ ). Differ- 
nces between groups were analysed using the Mann–Whitney U - 
est and Fisher’s exact test for continuous variables and categori- 
al variables, respectively. Significance was assigned at a P -value of 
 0.05. 
. Results 
.1. Patient characteristics ( Table 1 ) 
The median age of the 413 patients with CDI was 76 years (in- 
erquartile range, 64–81 years). The most common underlying co- 
orbidity was malignancy (16.0%; n = 66), followed by diabetes 
ellitus (15.3%; n = 63), end-stage renal disease (15.3%; n = 63) 
nd cerebrovascular disease (10.2%; n = 42). Only five patients 
1.2%) had a history of pulmonary tuberculosis. Two-thirds of the 
atients (66.8%; n = 276) had a hospital-acquired infection. Most 
f the patients (82.3%; n = 340) had a history of antimicrobial us- 
ge, and the most common antimicrobial agent was a β-lactam/ β- 
actamase inhibitor combination (34.6%; n = 143), followed by 
xtended-spectrum cephalosporins (24.5%; n = 101) and fluoro- 
uinolones (16.7%; n = 69). Antimicrobial therapy was discontin- 
ed in 26.6% of patients ( n = 110), and metronidazole and van- 
omycin were administered to 61.3% ( n = 253) and 36.1% ( n = 149)
f patients, respectively. Only 42 cases of recurrent CDI in 29 pa- 
ients (7.0%) were observed within the 3-month follow-up period, 
nd all-cause in-hospital mortality of patients with CDI was 14.8% 
 n = 61). 
.2. Characteristics of Clostridioides difficile isolates ( Table 1 ) 
The most common RTs of the C. difficile isolates were RT018 
21.8%; n = 90), RT014/020 (15.5%; n = 64), RT002 (7.7%; n = 32), 
T012 (6.5%; n = 27) and RT017 (5.6%; n = 23). Only five RT027 
solates (1.2%) were identified, and the remaining 104 C. difficile 
solates were included in 42 different RTs. Most of the C. difficile 
solates were non-susceptible to clindamycin (91.5%; n = 378) and 
mipenem (92.0%; n = 380), and almost one-half of them were 
on-susceptible to cefotetan (47.5%; n = 196) and moxifloxacin 
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Table 1 
Clinical characteristics of patients with culture-confirmed Clostridioides difficile infection (CDI) and pathogen profiles, stratified according to their 
non-susceptibility to rifaximin 
Variable Total ( n = 413; 100%) Rifaximin-NS ( n = 81; 19.6%) Rifaximin-S ( n = 332; 80.4%) P -value a 
Patient characteristics 
Age (years) [median (IQR)] 76 (64.0–81.0) 77.0 (70.0–83.0) 76.0 (63.0–81.0]) 0.192 
Male sex 177 (42.9) 36 (44.4) 141 (42.5) 0.844 
Underlying co-morbidities 
Malignancy 66 (16.0) 11 (13.6) 55 (16.6) 0.625 
Diabetes mellitus 63 (15.3) 12 (14.8) 51 (15.4) 0.999 
Cardiovascular disease 16 (3.9) 4 (4.9) 12 (3.6) 0.816 
Cerebrovascular disease 42 (10.2) 9 (11.1) 33 (9.9) 0.914 
End-stage renal disease 63 (15.3) 12 (14.8) 51 (15.4) 0.999 
Liver cirrhosis 11 (2.7) 2 (2.5) 9 (2.7) 0.999 
Chronic pulmonary disease 29 (7.0) 3 (3.7) 26 (7.8) 0.289 
Pulmonary tuberculosis 5 (1.2) 5 (6.2) 0 (0) –
Hospital-acquired infection 276 (66.8) 60 (74.1) 216 (65.1) 0.158 
Fever 61 (14.8) 13 (16.0) 48 (14.5) 0.909 
Accompanying PMC 75 (18.2) 14 (17.3) 61 (18.4) 0.946 
Severe CDI 81 (19.6) 14 (17.3) 67 (20.2) 0.539 
Laboratory findings 
WBC count > 15 000 cells/ μL 84 (20.3) 16 (19.8) 68 (20.5) 0.999 
Albumin < 2.5 g/dL 107 (25.9) 24 (29.6) 83 (25.0) 0.477 
Proton pump inhibitor 46 (11.1) 12 (14.8) 34 (10.2) 0.358 
Previous antibiotic usage 340 (82.3) 71 (87.7) 269 (81.0) 0.194 
β-Lactam/ β-lactamase inhibitors 143 (34.6) 28 (34.6) 115 (34.6) 0.999 
1/2G cephalosporins 24 (5.8) 4 (4.9) 20 (6.0) 0.913 
3/4G cephalosporins 101 (24.5) 23 (28.4) 78 (23.5) 0.438 
Carbapenems 59 (14.3) 16 (19.8) 43 (13.0) 0.164 
Fluoroquinolones 69 (16.7) 18 (22.2) 51 (15.4) 0.188 
Rifaximin 4 (1.0) 3 (3.7) 1 (0.3) 0.030 
Treatment 
Discontinued antimicrobial therapy 110 (26.6) 21 (25.9) 89 (26.8) 
Metronidazole 253 (61.3) 55 (67.9) 198 (59.6) 0.302 
Vancomycin 149 (36.1) 28 (34.6) 121 (36.4) 0.752 
Recurrence 29 (7.0) 8 (9.9) 21 (6.3) 0.329 
In-hospital mortality 61 (14.8) 18 (22.2) 43 (13.0) 0.064 
Pathogen characteristics 
Ribotype < 0.001 
018 90 (21.8) 46 (56.8) 44 (13.3) 
014/020 64 (15.5) 2 (2.5) 62 (18.7) 
002 32 (7.7) 3 (3.7) 29 (8.7) 
012 27 (6.5) 1 (1.2) 26 (7.8) 
046 23 (5.6) 4 (4.9) 19 (5.7) 
106 23 (5.6) 2 (2.5) 21 (6.3) 
017 23 (5.6) 13 (16.0) 10 (3.0) 
001 22 (5.3) 0 (0) 22 (6.6) 
027 5 (1.2) 5 (6.2) 0 (0) 
Others 104 (25.2) 5 (6.2) 99 (29.8) 
Toxins 
tcdA + / tcdB + 368 (89.1) 62 (76.5) 306 (92.2) 0.011 
tcdA –/ tcdB + 29 (7.0) 13 (16.0) 16 (4.8) 0.011 
tcdA + / tcdB + , cdtA + / cdtB + 16 (3.9) 6 (7.4) 10 (3.0) 0.129 
Non-susceptibility to: 
Ampicillin 270 (65.4) 66 (81.5) 204 (61.4) 0.001 
Cefotetan 196 (47.5) 71 (87.7) 125 (37.7) < 0.001 
Clindamycin 378 (91.5) 77 (95.1) 301 (90.7) 0.293 
Imipenem 380 (92.0) 77 (95.1) 303 (91.3) 0.367 
Chloramphenicol 10 (2.4) 6 (7.4) 4 (1.2) 0.004 
Tetracycline 80 (19.4) 17 (21.0) 63 (19.0) 0.800 
Moxifloxacin 182 (44.1) 75 (92.6) 107 (32.2) < 0.001 
Metronidazole 0 (0) 0 (0) 0 (0) –
Vancomycin 0 (0) 0 (0) 0 (0) –
NOTE: Data are n (%) unless otherwise stated. 
NS, non-susceptible; S, susceptible; IQR, interquartile range; PMC, pseudomembranous colitis; WBC, white blood cell; 1/2G, first and second- 
generation; 3/4G, third and fourth-generation. 









44.1%; n = 182). All C. difficile isolates collected in this study ex- 
ibited susceptibility to traditionally used anti-CDI drugs includ- 
ng vancomycin and metronidazole. Antimicrobial susceptibilities 
f the isolates stratified according to their RTs are summarised in 
able 2 . 48 .3. Rifaximin-non-susceptible Clostridioides difficile infection 
A substantial portion (19.6%; n = 81) of the 413 C. difficile clin- 
cal isolates described in this study was non-susceptible to rifax- 
min. The most common RTs for the rifaximin-non-susceptible C. 
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Table 2 
Non-susceptibility rates [ n (%)] of Clostridioides difficile isolates stratified according to ribotype (RT) 
Antimicrobial 
RT018 
( n = 90; 
21.8%) 
RT014/020 
( n = 64; 
15.5%) 
RT002 
( n = 32; 
7.7%) 
RT012 
( n = 27; 
6.5%) 
RT106 
( n = 23; 
5.6%) 
RT017 
( n = 23; 
5.6%) 
RT046 
( n = 23; 
5.6%) 
RT001 
( n = 22; 
5.3%) 
RT027 
( n = 5; 
1.2%) 
Others RTs 
( n = 104; 
25.2%) 
Ampicillin 77 (85.6) 35 (54.7) 30 (93.8) 16 (59.3) 13 (56.5) 18 (78.3) 20 (87.0) 7 (31.8) 5 (100) 49 (47.1) 
Cefotetan 89 (98.9) 8 (12.5) 24 (75.0) 6 (22.2) 4 (17.4) 22 (95.7) 10 (43.5) 8 (36.4) 5 (100) 20 (19.2) 
Clindamycin 89 (98.9) 59 (92.2) 30 (93.8) 27 (100) 20 (87.0) 22 (95.7) 19 (82.6) 19 (86.4) 5 (100) 88 (84.6) 
Imipenem 89 (98.9) 57 (89.1) 32 (100) 23 (85.2) 21 (91.3) 22 (95.7) 21 (91.3) 20 (90.9) 5 (100) 90 (86.5) 
Chloramphenicol 2 (2.2) 0 (0) 0 (0) 0 (0.0) 0 (0) 4 (17.4) 2 (8.7) 1 (4.5) 1 (20.0) 0 (0) 
Tetracycline 1 (1.1) 0 (0) 0 (0) 9 (33.3) 0 (0) 20 (87.0) 19 (82.6) 18 (81.8) 0 (0) 13 (12.5) 
Moxifloxacin 89 (98.9) 6 (9.4) 22 (68.8) 2 (7.4) 1 (4.3) 18 (78.3) 7 (30.4) 13 (59.1) 5 (100) 19 (18.3) 
Rifaximin 46 (51.1) 2 (3.1) 3 (9.4) 1 (3.7) 2 (8.7) 13 (56.5) 4 (17.4) 0 (0) 5 (100) 5 (4.8) 
Metronidazole 0 (0.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Vancomycin 0 (0) 0 (0) 0 (0) 0 0.0 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Table 3 
Amino acid substitutions in the β subunit of the bacterial RNA polymerase (RpoB) in the causative Clostridioides difficile isolates exhibiting non- 
susceptibility to rifaximin 
Ribotype No. of isolates 
Amino acid substitution in RpoB Rifampicin MIC ( μg/mL) 
L487 D492 S498 H502 R505 I548 S550 0.03 0.06 0.12 0.25 0.5 1 2 > 128 
018 29 K M 29 
6 N K 6 
4 S K 4 
4 N 1 2 1 
1 K 1 
1 T 1 
1 Y 1 
017 12 N K 12 
1 T N K 1 
027 4 K M 4 
1 K 1 
106 2 2 
046 3 K M 3 
1 Y 1 
014/020 2 K 2 
002 1 E K 1 
2 2 
012 1 K M 1 
163 1 K 1 
159 1 K 1 
078 1 1 
NT 1 Y 1 
NT 1 1 











































ifficile isolates were RT018 (56.8%; 46/81), RT017 (16.0%; n = 13) 
nd RT027 (6.2%; n = 5) ( Table 1 ). Rifaximin-non-susceptible 
. difficile isolates exhibited higher rates of non-susceptibility to 
ost of the other drugs evaluated in this study compared with 
ifaximin-susceptible isolates, especially to ampicillin (81.5% vs. 
1.4%; P = 0.001), cefotetan (87.7% vs. 37.7%; P < 0.001), chlo- 
amphenicol (7.4% vs. 1.2%; P = 0.004) and moxifloxacin (92.6% 
s. 32.2%; P < 0.001) ( Table 1 ). In addition, strains collected from
ll five patients with a previous history of pulmonary tuberculosis 
xhibited rifaximin non-susceptibility. Previous antimicrobial treat- 
ent using rifaximin was also more frequently identified in pa- 
ients with rifaximin-non-susceptible CDI [3.7% (3/81) versus 0.3% 
1/332); P = 0.030] ( Table 1 ). 
.4. Amino acid substitutions in RpoB in rifaximin-non-susceptible 
lostridioides difficile isolates 
Rifaximin MICs for the 81 C. difficile isolates ranged from 0.03 
g/mL to > 128 μg/mL (MIC 50 , > 128 μg/mL; MIC 90 , > 128 μg/mL)
 Table 3 ). Nine RpoB amino acid substitutions were identified in 
his study, with most of these amino acid substitutions being pre- 
iously reported [20–22] . The R505K amino acid substitution was 
dentified in 65 isolates, with an additional I548M substitution in 
7 isolates, H502N substitution in 18 isolates, L487S substitution 49 n 4 isolates, and S498T and H502N substitution in 1 isolate; all of 
hem exhibited very high MICs for rifaximin ( > 128 μg/mL). Four 
solates carried the H502N substitution alone, with these isolates 
xhibiting lower MICs (ranging from 0.5 μg/mL to 2 μg/mL). Fi- 
ally, four isolates exhibiting MICs of 0.03 μg/mL did not show 
ny substitution in their RpoB amino acid sequences ( Table 3 ). 
. Discussion 
National monitoring of antimicrobial resistance in clinically im- 
ortant pathogens is essential for preventing the dissemination of 
ultidrug-resistant organisms; C. difficile has been identified by 
he US Centers for Disease Control and Prevention (CDC) as one 
uch pathogen that needs urgent monitoring [23] . A new surveil- 
ance system for antimicrobial resistance (Kor-GLASS) was initi- 
ted in South Korea in 2016 using the World Health Organization’s 
LASS programme as a model [13] . As a part of Kor-GLASS, mon- 
toring the antimicrobial resistance of C. difficile isolates was initi- 
ted at two sentinel hospitals in 2018. Isolates from clinical CDIs 
re collected and subjected to antimicrobial susceptibility testing 
or the first-line drugs used in the treatment of these infections 
nd any drugs that could be risk factors for developing CDI under 
his programme. This surveillance programme include characteri- 
ation of the toxin genes as well as ribotyping of each isolate. 






































































[  RT018 C. difficile strains have been shown to be disseminated 
n South Korea since 2006 and have been the most common RT 
ince 2009 [ 24 , 25 ]. RT018 clones exhibit high levels of resistance to
mpicillin, cefotetan, imipenem and moxifloxacin, which have been 
uggested as a contributing factor to their dominance [26] . In this 
tudy, RT018 was still the most common RT, and more than one- 
alf of the RT018 isolates were non-susceptible to rifaximin. In ad- 
ition, three of the four patients with CDIs who had been exposed 
o rifaximin within the last 3 months were infected by rifaximin- 
on-susceptible C. difficile strains, and all five patients with a his- 
ory of pulmonary tuberculosis were infected with rifaximin-non- 
usceptible C. difficile . Reigadas et al. reported that a high percent- 
ge of rifaximin-non-susceptible CDI cases were detected in cir- 
hotic patients receiving rifaximin to prevent hepatic encephalopa- 
hy [27] . The successful clonal expansion of RT018 strains in South 
orea where the incidence of pulmonary tuberculosis is still high 
ay result in a high proportion of rifaximin-non-susceptible C. dif- 
cile strains. 
Sequence analysis of rpoB from the rifaximin-non-susceptible C. 
ifficile isolates identified nine amino acid substitutions. Of these, 
hree substitutions (L487S, D492E and H502K) were novel and 
he remaining six substitutions (S498T, H502N, H502Y, R505K, 
548M and S550Y) have been described in previous studies [20–
2] . Among the 68 C. difficile isolates exhibiting very high MICs 
or rifaximin ( > 128 μg/mL), 65 isolates had the R505K polymor- 
hism alone or in conjunction with one or two additional amino 
cid substitutions, which are believed to affect the direct interac- 
ion of rpoB with rifamycin [20] . 
A limitation of this study is that the sentinel hospitals are ge- 
graphically restricted to a single country, South Korea, where the 
acial homogeneity is very high. Therefore, ethnic or racial diver- 
ity was not considered in this study. In addition, a lack of func- 
ional evaluation of the novel amino acid substitutions in RpoB 
ould be another potential limitation. Further studies should be 
onducted to evaluate the possible effects of these polymorphisms. 
In conclusion, this multicentre observational study shows that 
he rifaximin-non-susceptibility rate in C. difficile isolates was very 
igh, with most of the non-susceptible strains belonging to RT018 
nd RT017, which are the most common RTs in South Korea. The 
uccess of these RTs may be facilitated by increased antimicrobial 
election pressure following rifaximin treatment associated with 
he high incidence of pulmonary tuberculosis in these populations. 
 continuous surveillance programme for investigating the molec- 
lar epidemiology of C. difficile is required. 
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